| scholarly article | Q13442814 |
| P356 | DOI | 10.1124/JPET.105.092312 |
| P698 | PubMed publication ID | 16188953 |
| P2093 | author name string | L Schild | |
| A C Ludolph | |||
| B Hengerer | |||
| F Gillardon | |||
| L Kussmaul | |||
| B Schwalenstoecker | |||
| C Dorner-Ciossek | |||
| E Buerger | |||
| K Klinder | |||
| R Danzeisen | |||
| V Krzykalla | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | enantiomer | Q494483 |
| P304 | page(s) | 189-199 | |
| P577 | publication date | 2005-09-27 | |
| P1433 | published in | Journal of Pharmacology and Experimental Therapeutics | Q1500272 |
| P1476 | title | Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]. | |
| P478 | volume | 316 |
| Q38552413 | AMPK Signalling and Defective Energy Metabolism in Amyotrophic Lateral Sclerosis |
| Q97519933 | Abnormal Mitochondrial Quality Control in Neurodegenerative Diseases |
| Q41217947 | Acidotoxicity and acid-sensing ion channels contribute to motoneuron degeneration |
| Q56839346 | Amyotrophic Lateral Sclerosis: An Aging-Related Disease |
| Q36202825 | Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole |
| Q46798019 | Amyotrophic lateral sclerosis. Current clinical trials and underlying pathomechanisms |
| Q37981224 | Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis |
| Q37299687 | Death receptor 6 (DR6) antagonist antibody is neuroprotective in the mouse SOD1G93A model of amyotrophic lateral sclerosis |
| Q48256015 | Dexpramipexole improves bioenergetics and outcome in experimental stroke |
| Q34744144 | Dexpramipexole is ineffective in two models of ALS related neurodegeneration |
| Q39344567 | Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial |
| Q54579499 | Dopamine D2 agonists, bromocriptine and quinpirole, increase MPP+ -induced toxicity in PC12 cells. |
| Q42153700 | Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency |
| Q36866600 | Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis |
| Q37867784 | Emerging targets and treatments in amyotrophic lateral sclerosis |
| Q52651163 | Energy metabolism in ALS: an underappreciated opportunity? |
| Q38223292 | Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs |
| Q37272764 | KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis. |
| Q39101800 | Metabolic Dysfunctions in Amyotrophic Lateral Sclerosis Pathogenesis and Potential Metabolic Treatments |
| Q33529864 | Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole |
| Q30412722 | Mitochondrial protectant pramipexole prevents sex-specific long-term cognitive impairment from early anaesthesia exposure in rats. |
| Q91048657 | Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent |
| Q33772181 | Molecular Dissection of Cyclosporin A's Neuroprotective Effect Reveals Potential Therapeutics for Ischemic Brain Injury |
| Q38156505 | Moving forward in clinical trials for ALS: motor neurons lead the way please |
| Q47221383 | Parkinson's disease-like midbrain hyperechogenicity is frequent in amyotrophic lateral sclerosis |
| Q34276055 | Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis |
| Q30445597 | R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS. |
| Q36639807 | Ribonuclease 4 protects neuron degeneration by promoting angiogenesis, neurogenesis, and neuronal survival under stress |
| Q45023714 | Safety and Tolerability of R(+) Pramipexole in Mild-to-Moderate Alzheimer's Disease |
| Q51536742 | Safety, Tolerability, and Pharmacokinetics of KNS-760704 (Dexpramipexole) in Healthy Adult Subjects |
| Q36494315 | State of the field: An informatics-based systematic review of the SOD1-G93A amyotrophic lateral sclerosis transgenic mouse model |
| Q57823172 | Synergistic Interaction Between Zinc and Reactive Oxygen Species Amplifies Ischemic Brain Injury in Rats |
| Q42161900 | Synthesis, Characterization, and Biological Evaluation of certain 6-methyl-2(3H)-benzo-1, 3-thiazolyl-1'-ethylidene-2-(o, p- Substituted Acetophenones) Hydrazine Analogs |
| Q30422273 | The abolishment of anesthesia-induced cognitive impairment by timely protection of mitochondria in the developing rat brain: the importance of free oxygen radicals and mitochondrial integrity |
Search more.